vs
ARTIVION, INC.（AORT）与Apyx Medical Corp（APYX）财务数据对比。点击上方公司名可切换其他公司
ARTIVION, INC.的季度营收约是Apyx Medical Corp的6.1倍（$116.0M vs $19.2M）。ARTIVION, INC.净利率更高（2.1% vs -6.8%，领先8.9%）。Apyx Medical Corp同比增速更快（34.7% vs 19.2%）。Apyx Medical Corp自由现金流更多（$-2.8M vs $-7.9M）。过去两年Apyx Medical Corp的营收复合增速更高（36.8% vs 9.1%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
Apyx Medical前身是博维医疗，是美国的医疗器械制造商，专注生产电外科产品与能源技术相关医疗设备，公司总部位于佛罗里达州克利尔沃特，在保加利亚设有生产工厂。
AORT vs APYX — 直观对比
营收规模更大
AORT
是对方的6.1倍
$19.2M
营收增速更快
APYX
高出15.5%
19.2%
净利率更高
AORT
高出8.9%
-6.8%
自由现金流更多
APYX
多$5.1M
$-7.9M
两年增速更快
APYX
近两年复合增速
9.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $19.2M |
| 净利润 | $2.4M | $-1.3M |
| 毛利率 | 63.1% | 62.6% |
| 营业利润率 | 9.2% | 0.1% |
| 净利率 | 2.1% | -6.8% |
| 营收同比 | 19.2% | 34.7% |
| 净利润同比 | 114.7% | 71.9% |
| 每股收益（稀释后） | $0.06 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTAPYX
| Q4 25 | $116.0M | $19.2M | ||
| Q3 25 | $113.4M | $12.9M | ||
| Q2 25 | $113.0M | $11.4M | ||
| Q1 25 | $99.0M | $9.4M | ||
| Q4 24 | $97.3M | $14.2M | ||
| Q3 24 | $95.8M | $11.5M | ||
| Q2 24 | $98.0M | $12.1M | ||
| Q1 24 | $97.4M | $10.2M |
净利润AORTAPYX
| Q4 25 | $2.4M | $-1.3M | ||
| Q3 25 | $6.5M | $-2.0M | ||
| Q2 25 | $1.3M | $-3.8M | ||
| Q1 25 | $-505.0K | $-4.2M | ||
| Q4 24 | $-16.5M | $-4.6M | ||
| Q3 24 | $-2.3M | $-4.7M | ||
| Q2 24 | $-2.1M | $-6.6M | ||
| Q1 24 | $7.5M | $-7.6M |
毛利率AORTAPYX
| Q4 25 | 63.1% | 62.6% | ||
| Q3 25 | 65.6% | 64.4% | ||
| Q2 25 | 64.7% | 62.3% | ||
| Q1 25 | 64.2% | 60.1% | ||
| Q4 24 | 63.2% | 63.0% | ||
| Q3 24 | 63.7% | 60.5% | ||
| Q2 24 | 64.6% | 61.7% | ||
| Q1 24 | 64.6% | 58.1% |
营业利润率AORTAPYX
| Q4 25 | 9.2% | 0.1% | ||
| Q3 25 | 11.1% | -6.5% | ||
| Q2 25 | 7.4% | -22.6% | ||
| Q1 25 | 2.2% | -32.4% | ||
| Q4 24 | 2.7% | -21.4% | ||
| Q3 24 | 4.6% | -31.6% | ||
| Q2 24 | 6.6% | -45.7% | ||
| Q1 24 | 26.0% | -64.6% |
净利率AORTAPYX
| Q4 25 | 2.1% | -6.8% | ||
| Q3 25 | 5.7% | -15.4% | ||
| Q2 25 | 1.2% | -33.2% | ||
| Q1 25 | -0.5% | -44.0% | ||
| Q4 24 | -16.9% | -32.5% | ||
| Q3 24 | -2.4% | -40.9% | ||
| Q2 24 | -2.2% | -54.0% | ||
| Q1 24 | 7.7% | -74.0% |
每股收益（稀释后）AORTAPYX
| Q4 25 | $0.06 | — | ||
| Q3 25 | $0.13 | — | ||
| Q2 25 | $0.03 | — | ||
| Q1 25 | $-0.01 | — | ||
| Q4 24 | $-0.40 | — | ||
| Q3 24 | $-0.05 | — | ||
| Q2 24 | $-0.05 | $-0.19 | ||
| Q1 24 | $0.18 | $-0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $31.7M |
| 总债务越低越好 | $215.1M | $37.5M |
| 股东权益账面价值 | $448.2M | $14.5M |
| 总资产 | $884.8M | $66.8M |
| 负债/权益比越低杠杆越低 | 0.48× | 2.58× |
8季度趋势，按日历期对齐
现金及短期投资AORTAPYX
| Q4 25 | $64.9M | $31.7M | ||
| Q3 25 | $73.4M | $25.1M | ||
| Q2 25 | $53.5M | $29.3M | ||
| Q1 25 | $37.7M | $31.0M | ||
| Q4 24 | $53.5M | $31.7M | ||
| Q3 24 | $56.2M | $28.0M | ||
| Q2 24 | $55.0M | $32.7M | ||
| Q1 24 | $51.1M | $37.3M |
总债务AORTAPYX
| Q4 25 | $215.1M | $37.5M | ||
| Q3 25 | $214.9M | $37.5M | ||
| Q2 25 | $215.6M | $37.5M | ||
| Q1 25 | $314.7M | $37.5M | ||
| Q4 24 | $314.3M | $37.5M | ||
| Q3 24 | $314.0M | $37.5M | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTAPYX
| Q4 25 | $448.2M | $14.5M | ||
| Q3 25 | $438.7M | $5.8M | ||
| Q2 25 | $419.9M | $7.3M | ||
| Q1 25 | $294.3M | $10.5M | ||
| Q4 24 | $276.2M | $14.2M | ||
| Q3 24 | $304.7M | $11.0M | ||
| Q2 24 | $295.1M | $14.7M | ||
| Q1 24 | $295.0M | $20.3M |
总资产AORTAPYX
| Q4 25 | $884.8M | $66.8M | ||
| Q3 25 | $857.7M | $57.4M | ||
| Q2 25 | $838.4M | $58.2M | ||
| Q1 25 | $791.2M | $60.2M | ||
| Q4 24 | $789.1M | $64.8M | ||
| Q3 24 | $803.1M | $60.7M | ||
| Q2 24 | $789.5M | $65.4M | ||
| Q1 24 | $784.0M | $70.7M |
负债/权益比AORTAPYX
| Q4 25 | 0.48× | 2.58× | ||
| Q3 25 | 0.49× | 6.41× | ||
| Q2 25 | 0.51× | 5.17× | ||
| Q1 25 | 1.07× | 3.57× | ||
| Q4 24 | 1.14× | 2.64× | ||
| Q3 24 | 1.03× | 3.40× | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $-2.5M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $-2.8M |
| 自由现金流率自由现金流/营收 | -6.9% | -14.6% |
| 资本支出强度资本支出/营收 | 23.7% | 1.4% |
| 现金转化率经营现金流/净利润 | 8.06× | — |
| 过去12个月自由现金流最近4个季度 | $839.0K | $-9.1M |
8季度趋势，按日历期对齐
经营现金流AORTAPYX
| Q4 25 | $19.6M | $-2.5M | ||
| Q3 25 | $22.3M | $-3.5M | ||
| Q2 25 | $15.0M | $-1.2M | ||
| Q1 25 | $-17.0M | $-702.0K | ||
| Q4 24 | $10.1M | $-2.9M | ||
| Q3 24 | $11.5M | $-4.4M | ||
| Q2 24 | $6.1M | $-4.3M | ||
| Q1 24 | $-5.5M | $-6.3M |
自由现金流AORTAPYX
| Q4 25 | $-7.9M | $-2.8M | ||
| Q3 25 | $17.7M | $-4.1M | ||
| Q2 25 | $11.7M | $-1.5M | ||
| Q1 25 | $-20.6M | $-757.0K | ||
| Q4 24 | $8.7M | $-3.2M | ||
| Q3 24 | $7.8M | $-4.6M | ||
| Q2 24 | $3.6M | $-4.6M | ||
| Q1 24 | $-9.1M | $-6.4M |
自由现金流率AORTAPYX
| Q4 25 | -6.9% | -14.6% | ||
| Q3 25 | 15.6% | -31.5% | ||
| Q2 25 | 10.4% | -13.2% | ||
| Q1 25 | -20.8% | -8.0% | ||
| Q4 24 | 9.0% | -22.4% | ||
| Q3 24 | 8.2% | -40.0% | ||
| Q2 24 | 3.7% | -38.0% | ||
| Q1 24 | -9.3% | -62.2% |
资本支出强度AORTAPYX
| Q4 25 | 23.7% | 1.4% | ||
| Q3 25 | 4.1% | 4.0% | ||
| Q2 25 | 2.9% | 2.3% | ||
| Q1 25 | 3.7% | 0.6% | ||
| Q4 24 | 1.5% | 1.7% | ||
| Q3 24 | 3.8% | 1.3% | ||
| Q2 24 | 2.6% | 2.4% | ||
| Q1 24 | 3.7% | 0.3% |
现金转化率AORTAPYX
| Q4 25 | 8.06× | — | ||
| Q3 25 | 3.42× | — | ||
| Q2 25 | 11.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
APYX
暂无分部数据
